Puretech Health (LON:PRTC)‘s stock had its “buy” rating restated by equities researchers at N+1 Singer in a note issued to investors on Thursday.
PRTC has been the subject of several other reports. Peel Hunt reiterated a “buy” rating and issued a GBX 259 ($3.47) price target on shares of Puretech Health in a report on Monday, September 25th. Numis Securities reiterated a “buy” rating and issued a GBX 207 ($2.77) price target on shares of Puretech Health in a report on Monday, September 25th. Jefferies Group reiterated a “buy” rating and issued a GBX 225 ($3.01) price target on shares of Puretech Health in a report on Wednesday, August 30th. Finally, Liberum Capital reissued a “buy” rating and issued a GBX 248 ($3.32) price objective on shares of Puretech Health in a research report on Wednesday, August 30th. Five equities research analysts have rated the stock with a buy rating, Puretech Health presently has a consensus rating of “Buy” and an average target price of GBX 248 ($3.32).
Shares of Puretech Health (LON PRTC) traded up GBX 1.88 ($0.03) during midday trading on Thursday, reaching GBX 126.25 ($1.69). The company had a trading volume of 243,476 shares, compared to its average volume of 41,921. Puretech Health has a 52-week low of GBX 110 ($1.47) and a 52-week high of GBX 139 ($1.86).
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health PLC and related companies with MarketBeat.com's FREE daily email newsletter.